Quoin Reaches 50% Enrollment in Netherton Syndrome Trial

Company anticipates releasing topline data later this year

Clinical-stage specialty pharmaceutical company Quoin Pharmaceuticals Ltd. (NASDAQ : QNRX), which focuses its research on rare and orphan diseases, has reached 50 percent enrollment in its open label Netherton Syndrome clinical trial.

The trial is evaluating the safety and efficacy of Quoin’s lead candidate, the topical lotion QRX003, in Netherton Syndrome patients who are currently receiving off-label systemic therapy, chiefly biologic therapy; it is being conducted under an open Investigational New Drug (IND).

After dosing the first patient in March, Quoin announced that it has now dosed its fifth patient out of a total of 10 expected to participate in the study.

The company is also conducting a double blinded, placebo controlled three arm study in 18 adult Netherton Syndrome patients.

Quoin believes the clinical data generated from both studies may be sufficient for a number of its eight global distribution partners to either seek formal regulatory approval or inclusion of the product in early access programs in their respective territories.

“We are very pleased with the level of interest that our two clinical trials have generated,” said Quoin CEO Dr. Michael Myers. “Reaching 50% enrollment for this, our open label study, is a very significant milestone and an important step forward for Quoin as we pursue the development of a safe and effective treatment for this devastating disease.”

In addition to Netherton Syndrome, Quoin’s development pipleline contains potential treatments for other rare diseases such as Scleroderma, Peeling Skin syndrome, SAM Syndrome and Epidermolysis Bullosa.

Earlier this year, Quoin completed a public offering with net proceeds of approximately $6 million. The company’s cash position is at its strongest level ever with a financial runway that extends well into the second half of 2024.